Karyopharm to Present SENTRY Trial Results at ASCO 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy KPTI?
Source: PRnewswire
- Clinical Trial Advancement: Karyopharm Therapeutics announced that its late-breaking abstract for the SENTRY trial will be presented orally at the 2026 ASCO Annual Meeting, showcasing the efficacy of 60 mg selinexor combined with ruxolitinib for myelofibrosis, which is expected to attract investor interest and boost market confidence.
- Trial Design Highlights: The SENTRY trial is a randomized, double-blind, placebo-controlled study involving JAKi-naïve myelofibrosis patients, with a 2:1 randomization to the selinexor arm, and co-primary endpoints including spleen volume reduction ≥35% and symptom score changes over 24 weeks, indicating potential clinical value of the treatment.
- Market Potential Analysis: With approximately 20,000 patients suffering from myelofibrosis in the U.S., Karyopharm's selinexor, as the first oral XPO1 inhibitor, could fill a significant market gap, addressing urgent patient needs for new therapies and potentially boosting company revenues significantly.
- International Expansion Strategy: Selinexor has received regulatory approvals in multiple countries, including the EU and China, and Karyopharm aims to enhance its global market presence through collaborations with local partners, strengthening its competitive position in the oncology treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KPTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KPTI
Wall Street analysts forecast KPTI stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.940
Low
6.00
Averages
13.83
High
21.00
Current: 8.940
Low
6.00
Averages
13.83
High
21.00
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Karyopharm to Present SENTRY Trial Results at ASCO 2026
- Clinical Trial Advancement: Karyopharm Therapeutics announced that its late-breaking abstract for the SENTRY trial will be presented orally at the 2026 ASCO Annual Meeting, showcasing the efficacy of 60 mg selinexor combined with ruxolitinib for myelofibrosis, which is expected to attract investor interest and boost market confidence.
- Trial Design Highlights: The SENTRY trial is a randomized, double-blind, placebo-controlled study involving JAKi-naïve myelofibrosis patients, with a 2:1 randomization to the selinexor arm, and co-primary endpoints including spleen volume reduction ≥35% and symptom score changes over 24 weeks, indicating potential clinical value of the treatment.
- Market Potential Analysis: With approximately 20,000 patients suffering from myelofibrosis in the U.S., Karyopharm's selinexor, as the first oral XPO1 inhibitor, could fill a significant market gap, addressing urgent patient needs for new therapies and potentially boosting company revenues significantly.
- International Expansion Strategy: Selinexor has received regulatory approvals in multiple countries, including the EU and China, and Karyopharm aims to enhance its global market presence through collaborations with local partners, strengthening its competitive position in the oncology treatment landscape.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
KPTI Shares Drop in Pre-Market Trading Despite Karyopharm's Myelofibrosis Treatment Achieving Key Goal — Retail Investors Skeptical of FDA Approval
Phase 3 Trial Results: Karyopharm's Phase 3 SENTRY trial showed that 50% of patients treated with selinexor combined with ruxolitinib achieved significant spleen volume reduction, compared to 28% with ruxolitinib alone, indicating promising efficacy for treating myelofibrosis.
Private Placement Announcement: Karyopharm announced a private placement deal with RA Capital Management to raise approximately $30 million, which is expected to support operations and planned clinical trials into the third quarter of 2026.
Stock Performance: Following the positive trial results, Karyopharm's stock initially gained but later reversed to a 13% decline in pre-market trading, reflecting mixed sentiment among investors regarding the FDA's potential approval of the drug.
Future Plans: The company plans to meet with the FDA to discuss next steps, including the possibility of filing a supplemental new drug application (sNDA) based on the trial data, which they believe could significantly improve clinical outcomes for patients.
See More
Karyopharm Seeks Label Expansion for Xpovio After Positive Trial Results
- Clinical Trial Success: Karyopharm Therapeutics announced that its lead asset, selinexor, succeeded in a late-stage trial for myelofibrosis, with over 35% of patients showing significant spleen volume reduction, indicating treatment efficacy.
- Safety Assessment: The SENTRY trial demonstrated that the combination of selinexor and JAK inhibitor ruxolitinib had a manageable safety and tolerability profile, although 15% of patients discontinued treatment due to adverse events, with no new safety signals identified.
- FDA Meeting Plans: Karyopharm plans to meet with the FDA to discuss the trial results and anticipates filing a supplemental new drug application for selinexor in myelofibrosis, which could further advance its market entry.
- Positive Stock Reaction: Following the announcement, Karyopharm's shares surged approximately 14%, and the company also revealed a $30 million private placement with RA Capital Management, enhancing its financial strength to support ongoing research and development.
See More
Karyopharm Therapeutics Secures $30M Private Placement
- Funding Size: Karyopharm Therapeutics announced a $30 million private placement with RA Capital, with an additional ~$44 million expected if accompanying warrants are fully exercised, indicating strong market confidence in its future growth.
- Share Sale Details: The private placement involves the sale of approximately 1.03 million shares at $6.785 each, along with about 3.39 million pre-funded warrants priced at $6.7849 each, providing substantial funding to support the company's clinical trial activities.
- Use of Proceeds: The proceeds will be allocated for general corporate purposes, particularly to support ongoing and planned clinical trial activities, which will aid in advancing its research and development efforts and enhance market competitiveness.
- Stock Price Reaction: Following the announcement of the private placement, Karyopharm's stock price jumped approximately 18% to $7.81 during pre-market trading on Tuesday, reflecting investor optimism regarding the company's future prospects.
See More
Karyopharm Reports Significant Results from SENTRY Trial for Myelofibrosis
- Significant Efficacy: Karyopharm's SENTRY trial demonstrated that the combination of 60 mg selinexor with ruxolitinib significantly increased the proportion of patients achieving a spleen volume reduction of 35% or more, indicating important clinical relevance in treating myelofibrosis.
- Survival Signal: The combination therapy showed a greater than 50% reduction in the risk of death at 24 weeks, suggesting its potential to improve overall survival rates for patients, which may provide new directions for future treatments.
- Good Safety Profile: No new safety signals were identified in the combination treatment group, and the adverse event rates were consistent with the known safety profiles of selinexor and ruxolitinib used individually, indicating good tolerability.
- Next Steps: Karyopharm plans to meet with the FDA to discuss the totality of the data and its supplemental new drug application, with expectations to submit relevant data in the second half of 2026 to further advance the clinical application of selinexor.
See More
Karyopharm to Present SENTRY Trial Results at ASCO 2026
- Clinical Trial Advancement: Karyopharm Therapeutics announced that its late-breaking abstract for the SENTRY trial will be presented orally at the 2026 ASCO Annual Meeting, showcasing the efficacy of 60 mg selinexor combined with ruxolitinib for myelofibrosis, which is expected to attract investor interest and boost market confidence.
- Trial Design Highlights: The SENTRY trial is a randomized, double-blind, placebo-controlled study involving JAKi-naïve myelofibrosis patients, with a 2:1 randomization to the selinexor arm, and co-primary endpoints including spleen volume reduction ≥35% and symptom score changes over 24 weeks, indicating potential clinical value of the treatment.
- Market Potential Analysis: With approximately 20,000 patients suffering from myelofibrosis in the U.S., Karyopharm's selinexor, as the first oral XPO1 inhibitor, could fill a significant market gap, addressing urgent patient needs for new therapies and potentially boosting company revenues significantly.
- International Expansion Strategy: Selinexor has received regulatory approvals in multiple countries, including the EU and China, and Karyopharm aims to enhance its global market presence through collaborations with local partners, strengthening its competitive position in the oncology treatment landscape.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
KPTI Shares Drop in Pre-Market Trading Despite Karyopharm's Myelofibrosis Treatment Achieving Key Goal — Retail Investors Skeptical of FDA Approval
Phase 3 Trial Results: Karyopharm's Phase 3 SENTRY trial showed that 50% of patients treated with selinexor combined with ruxolitinib achieved significant spleen volume reduction, compared to 28% with ruxolitinib alone, indicating promising efficacy for treating myelofibrosis.
Private Placement Announcement: Karyopharm announced a private placement deal with RA Capital Management to raise approximately $30 million, which is expected to support operations and planned clinical trials into the third quarter of 2026.
Stock Performance: Following the positive trial results, Karyopharm's stock initially gained but later reversed to a 13% decline in pre-market trading, reflecting mixed sentiment among investors regarding the FDA's potential approval of the drug.
Future Plans: The company plans to meet with the FDA to discuss next steps, including the possibility of filing a supplemental new drug application (sNDA) based on the trial data, which they believe could significantly improve clinical outcomes for patients.
See More
Karyopharm Seeks Label Expansion for Xpovio After Positive Trial Results
- Clinical Trial Success: Karyopharm Therapeutics announced that its lead asset, selinexor, succeeded in a late-stage trial for myelofibrosis, with over 35% of patients showing significant spleen volume reduction, indicating treatment efficacy.
- Safety Assessment: The SENTRY trial demonstrated that the combination of selinexor and JAK inhibitor ruxolitinib had a manageable safety and tolerability profile, although 15% of patients discontinued treatment due to adverse events, with no new safety signals identified.
- FDA Meeting Plans: Karyopharm plans to meet with the FDA to discuss the trial results and anticipates filing a supplemental new drug application for selinexor in myelofibrosis, which could further advance its market entry.
- Positive Stock Reaction: Following the announcement, Karyopharm's shares surged approximately 14%, and the company also revealed a $30 million private placement with RA Capital Management, enhancing its financial strength to support ongoing research and development.
See More
Karyopharm Therapeutics Secures $30M Private Placement
- Funding Size: Karyopharm Therapeutics announced a $30 million private placement with RA Capital, with an additional ~$44 million expected if accompanying warrants are fully exercised, indicating strong market confidence in its future growth.
- Share Sale Details: The private placement involves the sale of approximately 1.03 million shares at $6.785 each, along with about 3.39 million pre-funded warrants priced at $6.7849 each, providing substantial funding to support the company's clinical trial activities.
- Use of Proceeds: The proceeds will be allocated for general corporate purposes, particularly to support ongoing and planned clinical trial activities, which will aid in advancing its research and development efforts and enhance market competitiveness.
- Stock Price Reaction: Following the announcement of the private placement, Karyopharm's stock price jumped approximately 18% to $7.81 during pre-market trading on Tuesday, reflecting investor optimism regarding the company's future prospects.
See More
Karyopharm Reports Significant Results from SENTRY Trial for Myelofibrosis
- Significant Efficacy: Karyopharm's SENTRY trial demonstrated that the combination of 60 mg selinexor with ruxolitinib significantly increased the proportion of patients achieving a spleen volume reduction of 35% or more, indicating important clinical relevance in treating myelofibrosis.
- Survival Signal: The combination therapy showed a greater than 50% reduction in the risk of death at 24 weeks, suggesting its potential to improve overall survival rates for patients, which may provide new directions for future treatments.
- Good Safety Profile: No new safety signals were identified in the combination treatment group, and the adverse event rates were consistent with the known safety profiles of selinexor and ruxolitinib used individually, indicating good tolerability.
- Next Steps: Karyopharm plans to meet with the FDA to discuss the totality of the data and its supplemental new drug application, with expectations to submit relevant data in the second half of 2026 to further advance the clinical application of selinexor.
See More
